Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Drug repurposing unveils new combinatorial treatments to treat mutant KRAS lung cancer

ABSTRACT: We report data on a drug combination with synergistic antitumor effect in KRAS-driven lung cancer. We used RNAseq to characterize the transcriptional changes elicited by each drug in a mutant KRAS lung cancer cell lines (H1792)

ORGANISM(S): Homo sapiens

PROVIDER: GSE161218 | GEO | 2023/08/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Drug repurposing unveils new combinatorial treatments to treat mutant KRAS lung cancer

Project description:Drug repurposing unveils new combinatorial treatments to treat mutant KRAS lung cancer

| PRJNA675881 | ENA

Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS mutant lung cancer

Project description:To determine the difference of gene expression profile in epithelial and mesenchymal KRAS mutant lung cancers, epithelial NCI-H358 cells were treated with TGFβ1 (4 ng/mL) or PBS for 14 days in order to induce epithelial to mesenchymal transition (EMT). Gene expression was determined in NCI-H358 cells before and after EMT induction. In addition, in order to investigate the effect of a MEK inhibitor trametinib on gene expression, mesenchymal NCI-H1792 cells were treated with 50 nM trametinib for 48 hours. Gene expression of H1792 cells for pre- and post-trametinib treatement was determined.

2017-03-15 | GSE79235 | GEO

ATAC-seq of lung cancer cell lines with doxycycline KRAS G12V and drug treatments

Project description:We modelled the effects of KRAS activation on three SCLC cell lines H2107, H82, H524 and investigated the effects of KRAS induction and various drug treatments on motif and chromatin accessibility profiles.

2021-08-17 | GSE160204 | GEO

KRAS

Project description:Monodelphis domestica KRAS, Monodelphis domestica KRAS proto-oncogene, GTPase (KRAS), mRNA. [Source:RefSeq mRNA;Acc:NM_001032981], is expressed in 2 baseline experiment(s);

| ENSMODG00000017458 | ExpressionAtlas

ATAC-seq of lung cancer cell lines with doxycycline KRAS G12V and drug treatments

Project description:ATAC-seq of lung cancer cell lines with doxycycline KRAS G12V and drug treatments

| PRJNA672329 | ENA

Kras

Project description:Rattus norvegicus Kras, KRAS proto-oncogene, GTPase [Source:RGD Symbol;Acc:2981], is differentially expressed in 25 experiment(s);

| ENSRNOG00000009338 | ExpressionAtlas

Kras

Project description:Rattus norvegicus Kras, KRAS proto-oncogene, GTPase [Source:RGD Symbol;Acc:2981], is expressed in 3 baseline experiment(s);

| ENSRNOG00000009338 | ExpressionAtlas

Disruption of STAT3 signaling promotes KRAS induced lung tumorigenesis

Project description:Oncogenic STAT3 functions are known in various malignancies. We found that STAT3 plays an unexpected tumor suppressive role in KRAS-mutant non-small-cell-lung cancer (NSCLC). In mice, tissue-specific inactivation of Stat3 resulted in increased Kras (G12D)-driven NSCLC initiation and malignant progression leading to markedly reduced survival. Clinically, low STAT3 expression levels correlate with poor survival in human lung adenocarcinoma patients with smoking history. Consistently, KRAS-mutant lung tumors showed reduced STAT3 levels. Mechanistically, we show that STAT3 controls NFÎºB-induced IL-8-expression by sequestering NFÎºB in the cytoplasm while IL-8 in turn regulates myeloid tumor infiltration and tumor vascularization thereby promoting tumor progression. These results identify a novel STAT3-NFÎºB-IL-8 axis in KRAS-mutant NSCLC with therapeutic and prognostic relevance WT: Control lung; KRAS: Lung tumors expressing KRAS G12D; KRAS STAT3 KO: Lung tumors expressing KRAS G12D- STAT3 deficient; tumors of four mice pooled per sample

2015-02-05 | E-GEOD-52798 | biostudies-arrayexpress

KRAS

Project description:Sus scrofa KRAS, KRAS proto-onco, GTPase [Source:VGNC Symbol;Acc:VGNC:89569], is expressed in 6 baseline experiment(s);

| ENSSSCG00000026969 | ExpressionAtlas

KRAS

Project description:Macaca mulatta KRAS, KRAS proto-onco, GTPase [Source:VGNC Symbol;Acc:VGNC:74205], is expressed in 3 baseline experiment(s);

| ENSMMUG00000015381 | ExpressionAtlas